CRISPR Therapeutics raises $64m 'validating' uncertain patent position

CRISPR Therapeutics, which is focused on developing drugs using CRISPR-Cas9 gene-editing technology, has added additional funds to its series A and series B rounds, which now total $89m. The "heavily oversubscribed" financings were led by GSK's venture arm SR One and Celgene, respectively, and included new investors New Enterprise Associates and Abingworth, along with founding investor Versant Ventures. The fresh cash includes $35m of new series A and $29m of new series B funds.

"We are a very attractive employer in this field, and we'll be making good use of that over the next six-to-nine months to assemble a strong R&D team in Cambridge...